Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform

by Juan Lopez, Benzinga Staff Writer

January 18, 2012 12:44 PM | 10 seconds read | Make a Comment

Rodman & Renshaw has changed its rating on Rexahn Pharmaceuticals

RNN

from Under Review to Market Perform after the company revealed a change in focus to its oncology portfolio.

Posted In: Upgrades Intraday Update Analyst Ratings Rodman & Renshaw

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.